Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086787 | 1.00 | MAPT (0.46) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL3905980 | 0.90 | MAPT (0.48) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL3905983 | 0.90 | MAPT (0.48) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL3904192 | 0.84 | PLK1 (0.50) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL3904188 | 0.84 | PLK1 (0.50) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL6087583 | 0.82 | MEN1 (0.46) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL6087576 | 0.82 | MEN1 (0.46) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL5174367 | 0.81 | MAPT (0.54) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL5174362 | 0.81 | MAPT (0.54) | MAPTKMT2AMEN1HSD17B10DHODH | |
| SCHEMBL3353294 | 0.81 | MEN1 (0.54) | MAPTKMT2AMEN1HSD17B10DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MAPT 1138/4885KMT2A 3723/4885MEN1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.